Steven Locnikar
Addiction Medicine · Scottsdale, AZNPI 1184932782
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,081 of the $6,753 with a category attached, or 60.4%. 25 manufacturers reported payments, led by USWM, LLC at 46.7% of the total. Reporting peaked in 2022 at $2,678 and has fallen 81.9% since, to $486 in 2025. Among addiction medicine clinicians in AZ with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 256 payments — averaging $26.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- USWM, LLC$3K
- Braeburn Inc.$588
- AbbVie$494
- Alkermes, Inc.$488
- MDD US Operations, LLC$416
- Indivior Inc.$357
- plus $1K from 19 others
What the payments were for
- Consulting fees$5608%
- Speaking & faculty fees$4206%
- Food & beverage$4,08160%
- Education$1562%
- Gifts$1,53623%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| USWM, LLC | 53 | $3,152 |
| Braeburn Inc. | 35 | $588 |
| AbbVie(2 entities) | 29 | $494 |
| Alkermes, Inc. | 22 | $488 |
| MDD US Operations, LLC | 34 | $416 |
| Indivior Inc. | 19 | $357 |
| Teva Pharmaceuticals USA, Inc. | 12 | $336 |
| Orexo US, Inc. | 11 | $184 |
| Almatica Pharma LLC | 7 | $131 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 5 | $100 |
| Lilly USA, LLC | 5 | $82 |
| Pfizer | 4 | $77 |
| Eisai Inc. | 3 | $49 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $46 |
| Amgen | 2 | $44 |
| Titan Pharmaceuticals, Inc. | 2 | $36 |
| Biohaven Pharmaceuticals, Inc. | 2 | $33 |
| Johnson & Johnson | 2 | $31 |
| Carestream Dental, LLC | 1 | $19 |
| Redhill Biopharma Inc. | 1 | $19 |
| GSK | 1 | $19 |
| Otsuka America Pharmaceutical, Inc. | 1 | $17 |
| Arbor Pharmaceuticals, Inc. | 1 | $15 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $12 |
| Itamar Medical Inc | 1 | $9 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ZIMHI$1,519
- LUCEMYRA$980
- BRIXADI$117
- Lucemyra/Lofexidine$109
How this compares
$6,753 in reported general payments places this provider in the 90th percentile of 37 addiction medicine providers in Arizona.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 22 | $2,259 |
| Naltrexone Hcl | 24 | $915 |
| Gabapentin | 56 | $627 |
| Buprenorphine Hcl | 24 | $336 |
| Quetiapine Fumarate | 11 | $258 |
| Trazodone Hcl | 41 | $195 |
| Propranolol Hcl | 21 | $114 |
| Diazepam | 11 | $43 |
| Lorazepam | 16 | $27 |
| Fluoxetine Hcl | 13 | $11 |
Paid to pharmacies, not to this prescriber.
Other addiction medicine in Scottsdale
- Ehab AbdallahScottsdale$865
- Michael LoesScottsdale$362
- Wen Hui CaiTucson$111K
- Wendell PhillipsPhoenix$16K
- Rosekamal McKinneyGlendale$5K
- Gerald HarrisPeoria$5K
- J Carvel JacksonMesa$3K
- Scott HavensPhoenix$3K
- Robert HalliganPhoenix$1K
- Michael CarltonPhoenix$918
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.